Biocon has introduced a novel therapy CIMIVIR-L for the treatment of Hepatitis C patients in India.
CIMIVIR-L is a fixed dose combination of Ledipasvir 90 mg and Sofosbuvir 400 mg, which is an equivalent of the product commercialised by Gilead Sciences in the US.
Further, CIMIVIR-L, a once-a-day oral therapy, will offer a convenient, effective and safe alternative to people infected with the Hepatitis-C virus (HCV). It is estimated that nearly one lakh people die annually in India from HCV infection and co-morbidities.
Ravi Limaye, President - Marketing, Biocon, said: "The introduction of CIMIVIR-LTM will strengthen Biocon’s current portfolio of virology products."
The Drugs Controller General of India (DCGI) has recently approved the sale of Sofosbuvir-Ledipasvir combination, which is being manufactured in India under a licence from Gilead.